RecruitingPhase 1NCT07713485

Study of XmAb412 in Healthy Participants

A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple-dose Escalation Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of XmAb412 in Healthy Adult Participants

Sponsor

Xencor, Inc.

Enrollment

128 participants

Start Date

Jul 13, 2026

Study Type

INTERVENTIONAL

Conditions

Not Applicable - Healthy Adult Participants

Summary

This Phase 1 Study will evaluate the safety, tolerability, pharmacokinectics and pharmacodynamics of XmAb412 in healthy adult participants

Eligibility

Min Age: 18 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Placebo and a drug called XmAb412 Monoclonal Bispecific Antibody for people with not applicable - healthy adult participants. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 55 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGXmAb412 Monoclonal Bispecific Antibody

Monoclonal Bispecific Antibody

DRUGPlacebo

Placebo

Locations(2)

Xencor Investigative Site

Joondalup, Western Australia, Australia

Xencor Investigative Site

Nedlands, Western Australia, Australia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07713485